Health Care [ 12/12 ] | Life Sciences Tools & Services [ 71/74 ]
NASDAQ | Common Stock
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally.
It operates through Core Illumina and GRAIL segments.
The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test.
In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications.
The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies.
It markets and distributes its products directly to customers, as well as through life-science distributors.
Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 24 | 0.36 Increased by +12.50% | 0.90 Decreased by -60.00% |
| May 2, 24 | 0.09 Increased by +12.50% | 0.04 Increased by +125.00% |
| Feb 8, 24 | 0.14 Increased by 0.00% | 0.02 Increased by +600.00% |
| Nov 9, 23 | 0.33 Decreased by -2.94% | 0.12 Increased by +175.00% |
| Aug 9, 23 | 0.32 Decreased by -43.86% | 0.02 Increased by +1.50 K% |
| Apr 25, 23 | 0.08 Decreased by -92.52% | 0.03 Increased by +166.67% |
| Feb 7, 23 | 0.14 Decreased by -81.33% | 0.10 Increased by +40.00% |
| Nov 3, 22 | 0.34 Decreased by -76.55% | 0.30 Increased by +13.33% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 1.08 B Decreased by -3.49% | 705.00 M Increased by +193.50% | Increased by +65.28% Increased by +196.88% |
| Jun 30, 24 | 1.11 B Decreased by -5.44% | -1.99 B Decreased by -749.57% | Decreased by -178.78% Decreased by -798.47% |
| Mar 31, 24 | 1.08 B Decreased by -1.01% | -126.00 M Decreased by -4.30 K% | Decreased by -11.71% Decreased by -4.34 K% |
| Dec 31, 23 | 1.12 B Increased by +3.51% | -176.00 M Decreased by -25.71% | Decreased by -15.69% Decreased by -21.46% |
| Sep 30, 23 | 1.12 B Increased by +0.36% | -754.00 M Increased by +80.24% | Decreased by -67.38% Increased by +80.31% |
| Jun 30, 23 | 1.18 B Increased by +1.20% | -234.00 M Increased by +56.26% | Decreased by -19.90% Increased by +56.78% |
| Mar 31, 23 | 1.09 B Decreased by -11.12% | 3.00 M Decreased by -96.51% | Increased by +0.28% Decreased by -96.08% |
| Dec 31, 22 | 1.08 B Decreased by -9.59% | -140.00 M Decreased by -225.00% | Decreased by -12.92% Decreased by -238.26% |